Drugmaker Egalet pursues restructuring through equity swap and acquisition

A Delaware bankruptcy judge has allowed US and UK companies in the pharma group Egalet to use lender cash to fund their operations, as they go through Chapter 11 to carry out a debt-to-equity swap and acquire a Philadelphia painkiller producer.

Get unlimited access to all Global Restructuring Review content